Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412262

Interdisciplinary Perspectives on Celiac Disease: Diagnostic, Nutritional, and Oral Health Implications

Saad Laiban B Al Rowaili [(1)] , Nada Jameel Mohamed Salamah [(2)] , Fahad Abdullah Hamood Alrowily [(3)] , Ahood Ramadan Alhddad [(4)] , Saud Abdulmohsen Alanzi [(3)] , Ayman Ahmed Al-Otaibi [(5)] , Abdulrhman Asker Almuathi , Mosallam saed Alattaf [(6)]

(1) Eradah (Al Amal) Mental Health Complex Dammam,Ministry of Health, Saudi Arabia,
(2) Madinah Alalawi health center, Ministry of Health, Saudi Arabia,
(3) Ministry Of Health, Saudi Arabia,
(4) King Abdulaziz Specialist Hospital , Ministry of Health, Saudi Arabia,
(5) Prince Miteb bin Abdulaziz Hospital, Al-Jouf, Ministry of Health, Saudi Arabia,
(6) Aseer poison center, Ministry of Health, Saudi Arabia

Abstract

Background: Celiac disease is a chronic, immune-mediated systemic disorder triggered by gluten ingestion in genetically susceptible individuals. It is characterized by small intestinal inflammation, villous atrophy, and malabsorption, leading to a wide spectrum of gastrointestinal and extraintestinal manifestations. With a global prevalence of approximately 1%, it is a common condition often underdiagnosed due to its heterogeneous clinical presentation.

Aim: This article provides a comprehensive, interdisciplinary review of celiac disease, focusing on its diagnostic pathways, nutritional management, and broader health implications, including significant oral health manifestations. The goal is to outline a collaborative care model for optimal patient outcomes.

Methods: The review synthesizes current guidelines and clinical practices, detailing the stepwise diagnostic process. This includes serological testing for anti-tissue transglutaminase IgA (with total IgA levels to check for deficiency) as the first-line investigation, followed by confirmatory histopathological analysis of duodenal biopsies. The cornerstone of management, a lifelong strict gluten-free diet (GFD), is examined in depth.

Results: Accurate diagnosis requires patients to be on a gluten-containing diet. A strict GFD leads to symptomatic relief, serological normalization, and mucosal healing. Management is complex, requiring ongoing nutritional counseling to prevent deficiencies and address challenges like cross-contamination. The disease is associated with complications including osteoporosis, infertility, and an increased risk of lymphoma if untreated.

Conclusion: Effective management of celiac disease necessitates a lifelong, strict gluten-free diet and a proactive, interprofessional healthcare team. This collaborative approach is essential for accurate diagnosis, effective patient education, prevention of complications, and improvement of long-term health and quality of life.

Keywords: Celiac Disease, Gluten-Free Diet, Malabsorption, Autoimmune Enteropathy, tTG-IgA, Interdisciplinary Care, Nutritional Deficiency.

1. Introduction

Celiac disease is a chronic, immune-mediated enteropathy precipitated by the ingestion of gluten, a composite of storage proteins found in wheat, barley, and rye, in genetically susceptible individuals.[1] Rather than being confined to the gastrointestinal tract, it is now widely recognized as a systemic autoimmune disorder with diverse clinical manifestations. The pathogenic process is driven by an abnormal immune response to gluten-derived peptides, particularly in individuals carrying HLA-DQ2 or HLA-DQ8 haplotypes, leading to a cascade of inflammatory events in the small intestinal mucosa.[1] This immunologic injury is characterized histologically by villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes, together with inflammatory infiltration of the lamina propria. These structural changes disrupt normal absorptive capacity and ultimately result in malabsorption of macronutrients and key micronutrients, including iron, folate, vitamin B12, and fat-soluble vitamins A, D, E, and K.[2] Clinically, celiac disease exhibits a broad spectrum of presentations. Classical gastrointestinal manifestations include chronic or recurrent diarrhea, abdominal pain or discomfort, bloating, flatulence, and, paradoxically, constipation in some patients.[2] Steatorrhea may be evident in more severe malabsorptive states. However, a growing recognition of atypical and extraintestinal presentations has reshaped the understanding of this condition. Extraintestinal manifestations may include unexplained fatigue, weight loss, iron-deficiency

*Corresponding author e-mail: salrowaili@moh.gov.sa (Saad Laiban B Al Rowaili).

Receive Date: 1 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

anemia refractory to oral supplementation, osteopenia or osteoporosis due to impaired calcium and vitamin D absorption, and various neurologic or psychiatric symptoms such as peripheral neuropathy or mood disturbances.[2] Dermatologic manifestations, most notably dermatitis herpetiformis, represent a cutaneous expression of gluten sensitivity. In pediatric populations, celiac disease may present with growth failure, delayed puberty, irritability, and abdominal distension, underscoring its impact on development and overall health (see Image. Intestinal Changes in Celiac Disease).[2]

Given this heterogeneity, accurate diagnosis requires a structured, stepwise approach. Serologic testing is the cornerstone of initial evaluation in patients with suspected celiac disease. The most sensitive and specific marker is the anti–tissue transglutaminase immunoglobulin A (tTG-IgA) antibody, which targets the autoantigen tissue transglutaminase, a key enzyme in the deamidation of gluten peptides.[3] Anti-endomysial antibodies (EMAs), also IgA-based, provide an additional, highly specific serologic marker.[3] Because selective IgA deficiency is more common in individuals with celiac disease than in the general population, total serum IgA measurement is recommended to avoid false-negative serologic results. In patients with IgA deficiency, IgG-based tests, such as tTG-IgG or deamidated gliadin peptide IgG, are preferred.[3][4] Despite advances in serologic testing, histologic confirmation via small intestinal biopsy remains the gold standard for diagnosis in most adults. Endoscopically guided biopsies of the distal duodenum and duodenal bulb allow direct assessment of mucosal architecture, permitting grading of villous atrophy and crypt hyperplasia and quantification of intraepithelial lymphocytes.[4] The biopsy not only confirms the diagnosis but also helps exclude alternative causes of enteropathy, such as infections, drug-induced injury, or inflammatory bowel disease. In certain pediatric cases with very high serologic titers and compatible clinical features, some guidelines propose limited biopsy-sparing diagnostic pathways; however, histologic assessment remains central in many clinical settings.[4][5]

The cornerstone of therapy for celiac disease is strict, lifelong adherence to a gluten-free diet (GFD).[3] This requires complete exclusion of wheat, barley, and rye, along with careful avoidance of cross-contamination and hidden sources of gluten in processed foods, medications, and supplements. When followed rigorously, a GFD leads to symptomatic improvement, normalization of serologic markers, and progressive mucosal healing in the majority of patients.[3][5] Restoration of normal intestinal architecture is typically associated with recovery of nutrient absorption, correction of anemia and metabolic bone disease, and reduction of long-term risks such as infertility, adverse pregnancy outcomes, and enteropathy-associated T-cell lymphoma.[4][5] Adherence to a GFD, however, can be challenging due to dietary restrictions, cost, limited food options, social constraints, and variable food labeling standards. For this reason, regular follow-up with a multidisciplinary team—including physicians, dietitians, and, when appropriate, dental and laboratory professionals—is essential for monitoring dietary adherence, evaluating persistent or recurrent symptoms, and detecting complications such as refractory celiac disease or associated autoimmune conditions.[3][5] Serial assessment of serologic markers, nutritional status, and, in selected cases, repeat endoscopy and biopsy, supports long-term disease control and optimizes patient outcomes.

Etiology

The etiology of celiac disease is complex and multifactorial, involving an interplay of genetic predisposition, environmental exposure, and immune dysregulation. Central to its pathogenesis is a strong genetic component linked primarily to human leukocyte antigen (HLA) class II genes. Most individuals diagnosed with celiac disease express either HLA-DQ2 or HLA-DQ8 haplotypes, making these genes necessary but not sufficient for disease development.[6] Indeed, approximately 30%–40% of the general population carries these genetic markers, yet only a small percentage ever develop celiac disease, indicating that additional environmental and immunologic factors are required to initiate the pathological cascade. Non-HLA genes also contribute to susceptibility, though their impact is significantly smaller, and research continues to identify additional loci associated with immune regulation and intestinal barrier function. The key environmental trigger is dietary gluten, a storage protein found in wheat, barley, and rye. Gluten is composed of several peptide fractions, with gliadin being one of the most immunogenic components. In genetically susceptible individuals, ingestion of gluten initiates a series of biochemical and immunological events. After gluten is consumed, digestive enzymes break it down into partially digested peptides, including gliadin fragments that are resistant to complete enzymatic degradation. These fragments then traverse the intestinal epithelium, where they are deamidated by the enzyme tissue transglutaminase-2 (tTG2). This deamidation enhances the binding affinity of gliadin peptides to HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells, effectively amplifying the immune response.[7]

Once presented to CD4+ T helper lymphocytes, these modified peptides trigger a vigorous inflammatory reaction within the lamina propria. Activated T cells release pro-inflammatory cytokines, such as interferon-gamma, which drive tissue injury and promote the development of villous atrophy and crypt hyperplasia. Concurrently, B-cell activation leads to the production of disease-specific autoantibodies, including anti-tTG, anti-endomysial, and anti-deamidated gliadin peptide antibodies. These

autoantibodies serve as valuable diagnostic markers but also participate in the perpetuation of tissue damage. Environmental influences beyond gluten exposure also appear to modulate disease risk. Early-life factors—including timing of gluten introduction, breastfeeding practices, gastrointestinal infections, microbiome composition, and mode of delivery—have been explored for their roles in triggering or modifying immune responses to gluten. While no single factor has been definitively proven to prevent or cause celiac disease, evidence suggests that alterations in gut permeability, dysbiosis, and viral infections may contribute to the loss of oral tolerance to gluten in predisposed individuals. Thus, the etiology of celiac disease reflects the convergence of a permissive genetic background, exposure to dietary gluten, and immune dysregulation that transforms a common dietary protein into a potent autoimmune trigger.

Epidemiology

Celiac disease is now recognized as a common global autoimmune enteropathy rather than a rare disorder limited to specific ethnic or geographic groups. Current estimates suggest that it affects approximately 1% of the world's population, although reported prevalence varies depending on the diagnostic method used and the population studied.[8] Serologic testing, which is more widely applied in large-scale screening, indicates a prevalence of around 1.4%, while small intestinal biopsy—the histologic gold standard but less frequently performed in population-based studies—yields a somewhat lower prevalence of about 0.7%.[8] This discrepancy likely reflects both the incomplete capture of subclinical disease by biopsy-based data and the fact that a substantial subset of seropositive individuals may have mild or patchy enteropathy that is missed or not evaluated histologically. Geographically, celiac disease demonstrates significant variation in prevalence. It is most commonly reported in populations of European descent, particularly in Western and Northern Europe, where systematic screening and heightened awareness have led to increased detection.[8] However, elevated rates have also been documented outside Europe, challenging the traditional perception of celiac disease as a predominantly Western condition. Notably, higher prevalence has been observed in parts of the Middle East, such as Saudi Arabia, and among the Saharawi people, an ethnic group indigenous to the Western Sahara, where gluten-containing diets have become widespread and genetic susceptibility is relatively frequent.[8] These findings underscore the importance of considering celiac disease in diverse ethnic and geographic populations, especially as globalization influences dietary patterns.

Sex distribution studies consistently show that women are diagnosed with celiac disease more frequently than men, with female-to-male ratios often approximating 2:1.[9] Several explanations have been proposed for this disparity. Biological factors, including hormonal influences and sex-related differences in immune regulation, may predispose women to a higher risk of autoimmune disorders in general, including celiac disease.[9] In addition, detection bias plays a role, as women may be more likely to seek medical care for gastrointestinal or systemic symptoms and therefore more frequently undergo diagnostic testing. Nonetheless, serologic screening in asymptomatic populations suggests that undiagnosed celiac disease may be more evenly distributed between sexes than clinical diagnosis rates imply, indicating that celiac disease may be under-recognized in men. Celiac disease shows a particularly strong association with other autoimmune conditions, reflecting shared immunogenetic pathways. Among individuals with type 1 diabetes mellitus, the prevalence of biopsy-confirmed celiac disease ranges from approximately 1.6% to as high as 16.4%, substantially exceeding that in the general population.[10] This clustering is thought to result from a combination of shared HLA susceptibility alleles—especially HLA-DQ2 and HLA-DQ8—and overlapping environmental or immunologic triggers that promote the breakdown of tolerance. Similarly, increased prevalence has been reported in patients with autoimmune thyroid disease, autoimmune liver disease, and selective IgA deficiency.[10] These associations have led to recommendations for targeted screening in high-risk groups, particularly patients with type 1 diabetes and first-degree relatives of those with confirmed celiac disease.

Familial aggregation of celiac disease is well documented. First-degree relatives of affected individuals have a markedly increased prevalence of about 7.5%, reflecting both shared genetic susceptibility and environmental factors.[11] Risk is highest in monozygotic twins, where concordance exceeds 70%, underscoring the strong genetic component of disease pathogenesis.[11] Among other first-degree relatives, siblings demonstrate a prevalence of approximately 8.9%, offspring 7.9%, and parents around 3.0%.[12] These gradients likely reflect differences in shared genetic load, environmental exposure, and perhaps age-related penetrance. Such data support routine screening of first-degree relatives with serologic testing, even in the absence of symptoms, as asymptomatic or "silent" celiac disease remains common in this high-risk group. Age at diagnosis also strongly influences epidemiologic patterns. Pediatric patients are more likely than adults to receive an earlier diagnosis, in part because they often present with more classic features of malabsorption, such as chronic diarrhea, abdominal distension, failure to thrive, and growth retardation.[13] These overt and alarming symptoms typically prompt early medical evaluation, leading to serologic testing and endoscopic confirmation. In contrast, adults frequently present with nonclassical or

extraintestinal manifestations, including iron-deficiency anemia, osteoporosis, chronic fatigue, abdominal discomfort, or subtle gastrointestinal complaints that may be attributed to functional disorders or other conditions.[13] As a result, diagnosis in adults is often delayed by years, and many cases remain undetected. This underdiagnosis contributes to a discrepancy between the apparent prevalence in children and adults, despite the lifelong nature of the disease.

The transition from pediatric to adult care represents another critical juncture influencing epidemiologic data. Adolescents and young adults, no longer under close parental supervision, may exhibit lower adherence to gluten-free dietary recommendations, miss follow-up appointments, or disengage from specialized care.[14] This can lead to underreporting and misclassification of celiac disease status in epidemiologic studies, particularly when reliance is placed on self-report or medical records that may not capture older childhood diagnoses. Moreover, some individuals diagnosed in early childhood who become asymptomatic and seronegative on a strict gluten-free diet may stop reporting celiac disease as an active condition, even though the underlying susceptibility and need for dietary vigilance persist.[14] Given that celiac disease is a lifelong autoimmune disorder without a definitive cure, its true prevalence should be comparable across age groups, assuming similar patterns of genetic susceptibility and dietary exposure. The observed differences between pediatric and adult prevalence figures are therefore best understood as artifacts of diagnostic disparities, variations in healthcare-seeking behavior, underrecognition of atypical presentations, and suboptimal long-term follow-up rather than genuine differences in disease occurrence.[13][14] As awareness increases and screening becomes more systematic across all age groups and risk categories, it is likely that the recognized prevalence of celiac disease will continue to rise, converging toward the true burden of this underdiagnosed global condition.[8–14]

Pathophysiology

Celiac disease is a prototypical example of an immune-mediated disorder in which genetic susceptibility, environmental exposure, and dysregulated immune responses intersect to produce chronic small intestinal injury. The central environmental trigger is dietary gluten, a protein present in wheat, barley, and rye, whose immunogenic components—especially gliadin—drive the pathological cascade. During normal digestion, gluten is broken down into smaller peptides, but in individuals with celiac disease, key gliadin-derived peptides resist complete proteolytic degradation. These partially digested peptides retain strong immunogenic properties and are capable of interacting directly with the intestinal mucosal immune system.[15][7] A critical early event in celiac disease pathophysiology is the passage of these gliadin peptides across the intestinal epithelial barrier into the lamina propria. In healthy individuals, the intestinal epithelium regulates the controlled passage of luminal antigens and maintains tolerance to dietary proteins. In celiac disease, however, gliadin itself has been shown to increase intestinal permeability by affecting tight junction integrity, a phenomenon often described as "leaky gut." This enhanced permeability allows larger quantities of immunogenic peptides to enter the lamina propria, where they encounter tissue transglutaminase (tTG), the major autoantigen in celiac disease.[16] Within the lamina propria, tTG catalyzes the deamidation of specific glutamine residues in gliadin peptides, converting them to glutamic acid. This deamidation step significantly increases the negative charge of the gliadin peptides and enhances their binding affinity to the antigen-presenting groove of HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells (APCs), such as dendritic cells and macrophages.[7] The formation of these peptide–HLA complexes is a pivotal step in pathogenesis and explains why the presence of HLA-DQ2 or HLA-DQ8 is almost universal in individuals with celiac disease. Without these HLA molecules, the autoimmune cascade is unlikely to initiate, even in the presence of gluten exposure.

The peptide–HLA complexes on APCs are subsequently presented to CD4+ T helper cells circulating in the lamina propria. In genetically predisposed individuals, these CD4+ T cells recognize the complexes as harmful and become activated, sparking a maladaptive immune response. This response unfolds through three major, interrelated pathways. First, activated CD4+ T cells release pro-inflammatory cytokines such as interferon-gamma and other mediators that drive mucosal inflammation, promote crypt hyperplasia, and induce destruction of the villous architecture, collectively manifesting as small intestinal enteropathy.[15] The resulting villous atrophy drastically reduces the absorptive surface area of the small intestine, leading to impaired nutrient absorption and the clinical picture of malabsorption. Second, B cells are stimulated in this inflammatory milieu and differentiate into plasma cells that produce disease-specific autoantibodies. Among these are anti–tissue transglutaminase IgA (tTG-IgA) and anti-endomysial antibodies, both of which serve as important serologic markers for diagnosis.[15] The presence of these autoantibodies reflects a breakdown in tolerance to tTG, a self-antigen that is normally innocuous. In healthy individuals, tTG participates in physiological processes such as wound healing and matrix stabilization without eliciting an immune response. In celiac disease, however, its interaction with gliadin peptides and subsequent presentation in the context of HLA-DQ2/DQ8 appears to convert tTG into an autoantigen, driving autoantibody formation. Third, cytotoxic CD8+ T cells and intraepithelial lymphocytes are recruited and activated, leading to

direct injury of intestinal epithelial cells. These cytotoxic cells attack enterocytes, exacerbating villous atrophy and further disrupting the integrity of the intestinal lining.[15][7] The cumulative effect of these immune processes is characteristic histologic damage: blunted or absent villi, elongated crypts, and dense lymphocytic infiltration of the epithelium and lamina propria. This structural derangement underlies the classical symptoms of diarrhea, weight loss, and nutrient deficiencies, while the chronic systemic inflammatory state contributes to extraintestinal manifestations such as fatigue, anemia, and osteoporosis.

Intestinal permeability itself plays a reinforcing role in this process. Gliadin-induced disruption of tight junction proteins allows for an increased flux of luminal antigens into the lamina propria, perpetuating the cycle of antigen presentation, T-cell activation, and inflammation.[16] Over time, this chronic inflammatory response may extend beyond the gut, contributing to systemic effects and the association of celiac disease with other autoimmune conditions. In healthy individuals, tTG remains functionally silent from an immunologic standpoint, as its normal enzymatic activity does not provoke antibody formation. By contrast, in celiac disease, tTG activity appears upregulated within inflamed tissue, leading to increased generation of deamidated gliadin peptides that are then more efficiently presented to CD4+ T cells in the context of HLA-DQ2 or HLA-DQ8.[1] Only individuals who express these specific HLA molecules can form the high-affinity peptide–HLA complexes necessary to initiate this autoimmune cascade. Nonetheless, the presence of HLA-DQ2 or HLA-DQ8, though necessary, is not sufficient for disease development; many people who carry these alleles tolerate gluten without ever manifesting celiac disease. This discrepancy underscores the role of additional environmental and immunologic factors. Infections have been implicated as potential triggers or modifiers of disease risk. Certain viral infections, such as rotavirus and adenovirus, may alter immune responses or increase intestinal permeability in ways that favor the loss of tolerance to gluten in genetically susceptible hosts.[17] Conversely, some studies suggest that infections with organisms such as Helicobacter pylori might exert a protective influence, perhaps by modulating the immune system or competing for mucosal niches.[1][17] Changes in the gut microbiome, which may follow antibiotic exposure or other environmental insults, have also been proposed to influence disease onset by affecting immune regulation and barrier function. Physiological stressors such as pregnancy or major surgery may similarly act as triggers in predisposed individuals by altering hormonal and immune homeostasis.[1]

Non-HLA genetic factors further contribute to disease susceptibility. Genome-wide association studies have identified multiple non-HLA loci involved in immune regulation, epithelial barrier integrity, and cytokine signaling that may modulate risk, although their individual contributions are modest compared to HLA genes. These additional variants may help explain why only a subset of HLA-DQ2/DQ8 carriers develop celiac disease, while others remain unaffected despite similar gluten exposure. In summary, the pathophysiology of celiac disease reflects a highly orchestrated but pathological interplay between dietary gluten, genetic predisposition, and immune dysregulation. In genetically susceptible individuals expressing HLA-DQ2 or HLA-DQ8, ingestion of gluten leads to the generation of deamidated gliadin peptides that are presented to CD4+ T cells, driving an inflammatory and autoimmune response characterized by cytokine release, autoantibody production, and cytotoxic epithelial injury.[1][7][15][16][17] This results in the hallmark intestinal damage and diverse systemic manifestations that define celiac disease.

Histopathology

The histopathology of celiac disease is defined by a characteristic pattern of immune-mediated injury to the small intestinal mucosa, reflecting the consequences of chronic inflammation triggered by exposure to dietary gluten in genetically susceptible individuals. Examination of duodenal or jejunal biopsies under high magnification reveals a constellation of architectural and inflammatory abnormalities that together constitute the classic appearance of celiac enteropathy (see Image. High Magnification Micrograph of Celiac Disease). The severity of these changes can vary widely, ranging from subtle alterations in intraepithelial lymphocyte distribution to complete villous flattening with profound crypt hyperplasia, depending on the duration of gluten exposure and the degree of immune activation.[18] A central histologic hallmark is villous atrophy, the flattening or blunting of the normally fingerlike villi that line the small intestinal mucosa. In healthy tissue, these villi dramatically increase the absorptive surface area, permitting efficient uptake of nutrients. In celiac disease, however, the persistent inflammatory response to gluten leads to progressive destruction and shortening of the villi, severely impairing nutrient absorption and contributing to clinical manifestations such as malabsorption, weight loss, and micronutrient deficiencies. The loss of villous height disrupts normal mucosal architecture and correlates with disease severity.

Accompanying villous atrophy is crypt hyperplasia, a compensatory response whereby the crypts of Lieberkühn—located at the base of the villi—undergo increased proliferation. This results in elongated, deepened crypt structures, reflecting accelerated epithelial cell turnover as the mucosa attempts to regenerate damaged villi. The combination of villous atrophy and crypt hyperplasia leads to a

significant reduction in the villous-to-crypt (V:C) ratio. In unaffected individuals, the normal V:C ratio is approximately 3:1. In untreated celiac disease, this ratio commonly drops below 2:1 and may reach 1:1 or lower in severe cases.[18] This abnormal ratio serves as a useful histologic indicator of disease activity and guides diagnostic interpretation. A third defining histopathologic feature is intraepithelial lymphocytosis, characterized by an increased number of intraepithelial lymphocytes (IELs), particularly CD8+ T cells, infiltrating the epithelial layer. These lymphocytes represent part of the immune response directed against gluten-derived peptides and play a key role in the epithelial damage that contributes to villous atrophy. IEL counts exceeding 25 lymphocytes per 100 enterocytes are typically considered abnormal and are frequently seen even in early or mild forms of the disease.[19] The lamina propria, located beneath the epithelial layer, also shows marked inflammatory changes. Increased numbers of lymphocytes, plasma cells, and occasionally eosinophils infiltrate the lamina propria, further contributing to tissue injury and mucosal dysfunction.[20] The presence of these inflammatory cell populations underscores the immunologically active environment within the small intestine in untreated celiac disease.



Fig. 1: Intestinal Changes in Celiac Disease.

Biopsy interpretation may incorporate the Marsh or modified Marsh classification system, which categorizes histologic severity from minimal inflammatory changes (Marsh I) to complete villous atrophy with crypt hyperplasia (Marsh III). Although histologic patterns can vary, the combination of villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis remains pathognomonic when correlated with serologic and clinical findings. Importantly, strict adherence to a gluten-free diet leads to significant histologic recovery in many patients. Numerous studies demonstrate that normalization of the V:C ratio and reduction of inflammatory infiltrates occur in most children within months of dietary modification and improve substantially in adults, though complete healing may take longer.[18] Persistent villous atrophy despite dietary adherence may indicate inadvertent gluten exposure or, more rarely, refractory celiac disease. Overall, the histopathologic features of celiac disease reflect a dynamic interplay between immune-mediated epithelial injury, compensatory mucosal regeneration, and chronic inflammation, forming the structural basis for the clinical consequences of this lifelong autoimmune condition.



Fig. 2: High Magnification Micrograph of Celiac Disease.

History and Physical

Celiac disease presents with a remarkably wide spectrum of clinical manifestations that span both gastrointestinal and extraintestinal systems, making the diagnostic process highly dependent on a detailed history and a thorough physical examination. The variability in presentation is influenced by factors such as age, duration of gluten exposure, genetic susceptibility, and the degree of intestinal mucosal injury. Because celiac disease is fundamentally an immune-mediated enteropathy, gastrointestinal symptoms are primarily related to malabsorption resulting from villous atrophy. In contrast, extraintestinal manifestations reflect the systemic impact of chronic inflammation, micronutrient deficiencies, and autoimmune processes.[11] Clinicians must recognize both classic and atypical presentations, as many patients—especially adults—may present without overt gastrointestinal complaints.

Gastrointestinal Symptoms

Among adults, hallmark gastrointestinal symptoms include chronic diarrhea and unexplained weight loss, both of which stem from impaired nutrient absorption due to villous blunting. Patients frequently report abdominal distension, bloating, excessive gas, and vague discomfort. Nausea and vomiting may be intermittently present, reflecting delayed gastric emptying or heightened sensitivity of the upper gastrointestinal tract. Steatorrhea—bulky, pale, foul-smelling stools—may occur when fat malabsorption is severe. Interestingly, constipation can also be a presenting symptom, contradicting the long-held belief that celiac disease manifests only with diarrhea. This illustrates the heterogeneity of gastrointestinal involvement across patient populations. In children, the gastrointestinal presentation often reflects dramatic effects on growth and development. Parents may observe poor weight gain or failure to thrive, which frequently coincides with decreased appetite and irritability. Chronic diarrhea is a common presenting symptom, though some children may instead exhibit intermittent vomiting, significant abdominal distension, or constipation. These

manifestations often lead to earlier clinical attention in pediatric populations compared to adults, where symptoms may evolve insidiously over years.

Extraintestinal Symptoms

Celiac disease is increasingly recognized for its broad systemic manifestations. Hematologic abnormalities are among the most common, with iron-deficiency anemia being a frequent indicator in adults and children. Fatigue, pallor, reduced exercise tolerance, and dyspnea are typical complaints. The impaired absorption of folate and vitamin B12 may also contribute to anemia and neurological dysfunction. Neurologic symptoms vary widely. Adults may report muscle weakness, paresthesias, ataxia, or chronic headaches. Some evidence suggests associations between celiac disease and neurocognitive conditions in children, including attention-deficit/hyperactivity disorder (ADHD) or developmental delays; however, causality remains uncertain and requires further study.[21] Musculoskeletal symptoms include chronic arthralgias, myalgias, and bone pain. Adults may have a history of fragility fractures related to osteopenia or osteoporosis, which result from long-standing vitamin D and calcium malabsorption.[22] In children, skeletal symptoms may correlate with impaired growth, reduced bone mineralization, and delayed puberty. Reproductive concerns also arise. Unexplained infertility, recurrent miscarriage, or adverse pregnancy outcomes may indicate untreated celiac disease. In children, short stature, dental enamel hypoplasia, and delayed pubertal development are important clues linked to nutrient deficiencies and chronic inflammation.[23]

Physical Examination Findings

A comprehensive physical examination may reveal findings that support the diagnosis. Adults and children may appear underweight, with reduced muscle bulk indicative of protein-energy malnutrition. Abdominal distension is common and may be accompanied by diffuse tenderness. Evidence of micronutrient deficiency may present as pallor, cheilosis, glossitis, or brittle nails. Musculoskeletal examination may uncover tenderness over long bones or reduced muscle strength. A classic and pathognomonic physical finding is dermatitis herpetiformis, a chronic, intensely pruritic vesicular rash typically distributed on extensor surfaces such as elbows, knees, buttocks, and scalp. The presence of this rash strongly suggests celiac disease and may lead to diagnosis even in individuals without gastrointestinal symptoms.[25] In summary, the history and physical examination in celiac disease require a high index of suspicion and an appreciation for the diverse presentations across age groups. Recognizing the combination of gastrointestinal and extraintestinal symptoms, along with key physical findings, is essential for timely diagnosis and optimal patient management.



Fig. 3: Symptoms of Celiac Disease.

Evaluation

Evaluation of suspected celiac disease requires a structured, evidence-based approach that integrates clinical, serologic, genetic, and histopathologic data. The 2023 American College of Gastroenterology (ACG) guidelines emphasize that all testing should ideally be performed while the patient is still consuming a gluten-containing diet, as withdrawal of gluten can rapidly normalize serologic markers and histologic findings, potentially leading to false-negative results.[20] In most cases, patients should ingest gluten regularly for at least 6 to 8 weeks prior to testing to ensure adequate antigenic stimulation of the immune response. The recommended initial serologic test is anti–tissue transglutaminase immunoglobulin A (tTG-IgA) in patients who are not IgA-deficient.[20] This assay offers high sensitivity and specificity and is widely available, making it the preferred first-line test in both adults and children. Because selective IgA deficiency is more common in individuals with celiac disease than in the general population, total serum IgA should be measured concurrently if IgA status is unknown. When total IgA is normal, tTG-IgA is a reliable screening tool. In contrast, in confirmed IgA deficiency, IgG-based serologic testing—such as tTG-IgG or deamidated gliadin peptide IgG—should be used.[11][20] A negative tTG-IgA result has a high negative predictive value, particularly in patients with low-to-moderate pretest probability of celiac disease. In such individuals, a normal tTG-IgA often effectively rules out the diagnosis.[11] However, in patients with a high pretest probability, such as children with unexplained growth failure, adults with unexplained infertility or recurrent pregnancy loss, or those with multiple autoimmune disorders, a negative tTG-IgA does not completely exclude disease. In these scenarios, clinicians must consider the possibility of seronegative celiac disease or technical and biological causes of false-negative results, including limited gluten exposure or early disease. Additional evaluation—such as repeat serology, IgG-based tests, or small bowel biopsy—may be warranted.[11]

Endomysial antibody (EMA) testing serves as an important adjunct when tTG-IgA results are borderline, equivocal, or discordant with clinical findings. EMA, which targets endomysial antigens and is assessed by indirect immunofluorescence, is highly specific for celiac disease.[11] In pediatric practice, some guidelines accept a non-biopsy diagnostic approach in children when tTG-IgA levels exceed 10 times the upper limit of normal and EMA is positive, provided the clinical picture is consistent and the family agrees to this strategy. However, EMA testing is more expensive, technically demanding, and operator-dependent than tTG-IgA, which limits its use as a primary screening tool. As such, EMA is generally reserved for confirmatory testing rather than initial evaluation. Genetic testing for HLA-DQ2 and HLA-DQ8 provides another valuable tool in the diagnostic algorithm, particularly in patients who have already initiated a gluten-free diet (GFD) and are unwilling or unable to resume gluten intake for the several weeks required prior to serologic and histologic testing.[11] A negative HLA-DQ2/DQ8 result essentially excludes celiac disease, given that these alleles are present in nearly all affected individuals. However, because approximately 30% to 40% of the general population carries these alleles, a positive result indicates only genetic susceptibility rather than confirming the disease.[11] Therefore, HLA testing is most useful for ruling out celiac disease in equivocal cases or in those already on a GFD, rather than as a general screening tool. Its higher cost and variable insurance coverage further limit routine use.

When tTG-IgA (or other appropriate serology) is positive, the next recommended step in both adults and children is esophagogastroduodenoscopy (EGD) with duodenal biopsies to confirm the diagnosis and characterize the degree of mucosal damage.[26][27][28] The ACG guidelines advise obtaining at least 4 biopsies from the distal duodenum and 1 or 2 from the duodenal bulb to account for patchy involvement and reduce the risk of sampling error.[11] Histologic features supportive of celiac disease include villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes. These findings, when correlated with compatible serology and clinical presentation, establish the diagnosis. Small bowel biopsy is especially critical in cases of seronegative disease or where non-celiac enteropathies (such as infection, drug-induced injury, or inflammatory bowel disease) must be excluded.[26][27] As with serology, patients must be consuming gluten regularly to ensure that characteristic histopathologic changes are present at the time of biopsy.[28] The 2023 ACG guidelines strongly recommend EGD with biopsies as the standard method for diagnostic confirmation. However, they acknowledge that some patients—both children and adults—may be unable or unwilling to undergo endoscopy due to comorbidities, resource limitations, or personal preference.[11] In such situations, clinicians may consider alternative diagnostic approaches using a combination of high-titer serology, HLA/genetic testing, and careful clinical correlation, recognizing that these strategies may carry a greater risk of diagnostic uncertainty. Shared decision-making is essential, with clear discussion of the benefits and limitations of biopsy and non-biopsy pathways. Routine population-wide screening for celiac disease is not generally recommended, primarily because the balance of benefits, harms, and costs has not been definitively established. Nevertheless, targeted testing is strongly advised for individuals at increased risk. First-degree relatives of patients with celiac disease (parents, siblings, and offspring) constitute a key high-risk group, with an estimated 10% to 15% lifetime risk of developing the condition.[11] In these individuals, intermittent serologic screening—particularly when symptoms develop—can facilitate earlier diagnosis.

Celiac disease is also significantly more prevalent in people with certain autoimmune disorders, such as type 1 diabetes mellitus, autoimmune thyroid disease, and autoimmune liver disease.[10][11] In these populations, screening is justified given the increased prevalence and potential impact of unrecognized celiac disease on metabolic control, bone health, and quality of life. Similarly, individuals with genetic syndromes such as Down syndrome and Turner syndrome have a higher prevalence of celiac disease and may benefit from periodic serologic evaluation.[11] In summary, evaluation of celiac disease relies on a methodical, guideline-driven approach grounded in clinical suspicion, gluten-dependent serologic testing, genetic analysis when appropriate, and confirmatory small bowel histology. Adhering to these principles ensures accurate diagnosis, minimizes false positives and negatives, and allows timely initiation of a gluten-free diet and appropriate long-term follow-up.

Treatment / Management

The primary therapeutic intervention for celiac disease is strict, lifelong adherence to a gluten-free diet (GFD), which remains the only proven and effective treatment. A GFD leads to symptom resolution, mucosal healing, correction of nutritional deficiencies, and prevention of long-term complications, including osteoporosis, infertility, and enteropathy-associated T-cell lymphoma. Most patients experience significant improvement within days to weeks of dietary modification. In one study, nearly 80% of individuals reported reduced diarrhea within 60 days of eliminating gluten from their diet, underscoring the rapid clinical benefits of gluten withdrawal.[11][29] Lifelong medical follow-up is particularly important to ensure normalization of intestinal architecture and, in pediatric patients, restoration of normal growth and development. Patients must avoid wheat, barley, and rye, all of which contain gluten. The widespread use of these grains worldwide makes the GFD challenging. Gluten-

free alternatives include rice, corn, quinoa, millet, buckwheat, sorghum, and amaranth, all of which offer safe substitutes for gluten-containing staples.[20] Patient education must emphasize the importance of avoiding cross-contamination during food preparation and storage, as even trace amounts of gluten can trigger immune activation. Processed foods, condiments, medications, and supplements may contain "hidden" sources of gluten, making food label literacy essential. Clinicians should encourage patients to look for certified "gluten-free" labels to ensure that products meet established safety standards. Consultation with registered dietitians is vital to help patients adopt and maintain long-term adherence to a GFD, identify nutritional gaps, and optimize meal planning. For individuals who remain symptomatic, the first step is evaluating compliance, which often requires a detailed dietary history and may include repeat serologic testing. Nonadherence may be unintentional, as gluten contamination is common, especially in shared kitchens and restaurant environments.[30][31]

The safety of oats in a GFD remains an area of evolving research. Pure, uncontaminated oats are generally considered safe for most individuals with celiac disease and offer nutritional benefits, including increased dietary fiber and protein. However, commercial oat products are frequently contaminated with wheat or barley. A minority of patients experience symptoms from avenin, an oat protein, which may cause immune reactivity similar to gluten. Long-term studies and major nutrition organizations, including the Academy of Nutrition and Dietetics, support the inclusion of certified gluten-free oats in a GFD, provided patients are monitored for any recurrence of symptoms.[32] Adherence to a GFD can impose financial, social, and psychological burdens. Gluten-free products are often more expensive and may have altered taste or texture. Families may struggle with whether to adopt a GFD for all members or prepare separate meals, which can increase cost and complicate meal planning. Eating outside the home presents additional challenges, as restaurant meals may contain hidden gluten or pose cross-contamination risks. Gluten-free beers made from sorghum, millet, rice, or buckwheat offer safe alternatives to traditional barley-based beer.[34] Nutritional monitoring is an integral component of management. Patients should be screened for deficiencies in iron, vitamin B12, folate, zinc, and fat-soluble vitamins, especially vitamin D. Bone density evaluation is important for individuals with risk factors for osteopenia or osteoporosis. Supplementation, including a gluten-free multivitamin, should be individualized based on laboratory findings and dietary intake. Associated conditions such as dermatitis herpetiformis, autoimmune thyroid disease, and peripheral neuropathy require ongoing surveillance.

The ACG recommends periodic monitoring of serologic markers, particularly tTG-IgA or DGP-IgG in IgA-deficient patients, as decreasing antibody titers typically indicate adherence and mucosal recovery.[35] Routine follow-up biopsies are not recommended for all patients but should be considered in those with persistent symptoms despite confirmed adherence to a GFD or when refractory celiac disease (RCD) is suspected. RCD is characterized by ongoing villous atrophy despite strict gluten avoidance and requires specialized evaluation. In such cases, small bowel biopsies and additional testing help distinguish RCD from other causes of enteropathy.[20] Ultimately, effective management of celiac disease requires a combination of strict dietary adherence, regular clinical follow-up, nutritional monitoring, and psychosocial support. A patient-centered, multidisciplinary approach improves symptom control, enhances quality of life, and minimizes long-term complications, ensuring optimal outcomes for individuals living with this lifelong autoimmune condition.

Differential Diagnosis

Distinguishing celiac disease from other gastrointestinal and systemic disorders is essential because many conditions present with overlapping symptoms, including chronic diarrhea, abdominal pain, bloating, fatigue, weight loss, and nutrient deficiencies. A comprehensive clinical assessment—supported by serologic testing for disease-specific antibodies, small bowel biopsies, and evaluation of histopathologic features—is necessary to ensure accurate diagnosis. In celiac disease, hallmark biopsy findings include villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis. When serologic markers such as tTG-IgA and EMA are negative, and duodenal biopsies do not show classic mucosal lesions, other etiologies should be considered. Non-celiac gluten sensitivity (NCGS) is a key differential diagnosis, as affected individuals experience gluten-related symptoms but lack the autoimmune and histologic features of celiac disease. Unlike celiac disease, NCGS does not demonstrate villous atrophy or elevate tTG-IgA, although patients often report symptomatic improvement on a GFD. Irritable bowel syndrome (IBS) is another common mimic, presenting with abdominal cramping, altered bowel habits, bloating, and discomfort. IBS does not involve mucosal injury, and symptoms often fluctuate with stress, diet, or alterations in gut motility. Inflammatory bowel disease, including Crohn disease and ulcerative colitis, can resemble celiac disease due to shared symptoms such as diarrhea, abdominal pain, and weight loss. However, endoscopic evaluation typically identifies colonic or transmural inflammation characteristic of IBD, distinguishing it from the small intestinal involvement seen in celiac disease. Lactose intolerance may present with bloating, gas, and diarrhea due to lactase deficiency; while this can occur

secondary to celiac-induced villous damage, it can also present independently and requires dietary assessment or breath testing to differentiate.

Small intestinal bacterial overgrowth (SIBO) results in bloating, diarrhea, and malabsorption, closely resembling celiac disease. Hydrogen breath testing or aspiration of jejunal fluid supports the diagnosis. Food allergies and carbohydrate intolerances—such as fructose or FODMAP sensitivities—may also cause abdominal discomfort and loose stools, necessitating elimination diets or allergen testing. Autoimmune enteropathy presents a far more severe phenotype, often with profound diarrhea and weight loss. Histologic findings may mimic celiac disease, but anti-enterocyte antibodies and lack of gluten response help differentiate it.[36] Tropical sprue is geographically restricted, presenting with malabsorption and villous atrophy similar to celiac disease, but it typically responds to antibiotic therapy rather than dietary restriction. Giardiasis is a parasitic infection that can cause villous blunting, crypt hyperplasia, and intraepithelial lymphocytosis, mimicking the histology of celiac disease. Identification of *Giardia* trophozoites or antigens is essential for diagnosis and rules out celiac disease in such cases.[37] Pancreatic insufficiency also causes steatorrhea and weight loss, but stool elastase testing can confirm exocrine pancreatic dysfunction.

Medication-induced enteropathies must also be considered. Drugs such as NSAIDs, olmesartan, chemotherapeutic agents, immunosuppressants, and certain antibiotics may cause villous injury and chronic diarrhea. While histopathologic changes can resemble celiac disease, resolution typically occurs with discontinuation of the offending medication rather than gluten withdrawal.[38] In pediatric populations, additional differential diagnoses include cow milk protein allergy, gastroesophageal reflux disease, cystic fibrosis, and wheat allergy, all of which may present with malabsorption, growth delay, or gastrointestinal distress. Sweat chloride testing, serum IgE levels, or trial elimination diets may be required to differentiate these conditions.

Accurate diagnosis relies on careful clinical correlation, laboratory evaluation, and histologic confirmation to ensure appropriate management and avoid unnecessary or ineffective dietary restrictions.

Prognosis

With prompt diagnosis and consistent adherence to a strict GFD, the prognosis for celiac disease is generally highly favorable. Most patients report significant improvement in gastrointestinal symptoms—such as diarrhea, bloating, and abdominal pain—within weeks, while systemic symptoms, including fatigue or anemia, may take longer to resolve. Histologic recovery of the small intestinal mucosa typically occurs within 6 to 24 months, with children often achieving mucosal healing more rapidly than adults. Early intervention and long-term dietary compliance are associated with reduced risks of complications, including malnutrition, micronutrient deficiencies, osteoporosis, and reproductive issues. Adherence to a GFD also significantly decreases the incidence of long-term complications such as autoimmune comorbidities and malignancies, including enteropathy-associated T-cell lymphoma and small bowel adenocarcinoma.[35][39] Despite the generally favorable outlook, prognosis is less favorable in cases of RCD, defined by persistent or recurrent symptoms and villous atrophy despite strict adherence to a GFD for at least 6 to 12 months. RCD affects approximately 1% of individuals with celiac disease and is classified into two types based on immunologic and histologic features. Type-1 RCD, the more common form, is associated with polyclonal intraepithelial lymphocytes and typically has a better prognosis. These patients may respond to nutritional support, corticosteroids, and immunosuppressive agents, with many achieving clinical stabilization and improved quality of life.

In contrast, RCD type-2 displays monoclonal or aberrant intraepithelial lymphocytes, reflecting a more aggressive disease phenotype. This form carries a markedly higher risk for progression to enteropathy-associated T-cell lymphoma, one of the most serious complications of celiac disease. Research into targeted therapies—including purine analogs, monoclonal antibodies, JAK1/JAK3 inhibitors, and autologous stem cell transplantation—offers promising avenues for improving outcomes in RCD type-2, although optimal management remains challenging. The 5-year survival rate for RCD type-2 is approximately 50%, underscoring the severity of this condition and the importance of ongoing clinical vigilance.[40] Continuous follow-up is essential for all patients with celiac disease. Regular monitoring includes assessment of dietary adherence, serologic markers, nutritional status, and evaluation for comorbid conditions. Comprehensive patient education, mental health support, and collaboration with dietitians play critical roles in sustaining long-term well-being. Ultimately, early diagnosis, strict lifelong adherence to a GFD, and routine medical follow-up significantly improve prognosis and quality of life for patients with celiac disease.

Complications

Celiac disease is associated with a diverse range of complications that arise primarily from chronic intestinal inflammation, villous atrophy, and malabsorption, as well as from systemic immune dysregulation. Many of these complications can be effectively prevented or mitigated through strict and sustained adherence to a GFD, underscoring the importance of early diagnosis and long-term patient engagement in disease management. One of the most frequent complications is malabsorption, which leads to nutrient deficiencies involving iron, folate, vitamin B12, calcium, and fat-soluble vitamins. These deficiencies may result in anemia, osteopenia, and osteoporosis, significantly increasing fracture risk in

adults. In children, chronic malabsorption contributes to growth failure, irritability, delayed puberty, and dental enamel defects. Gastrointestinal malignancies represent one of the most serious complications of untreated or poorly managed celiac disease. Patients have a higher incidence of enteropathy-associated T-cell lymphoma and small intestinal adenocarcinoma, conditions that substantially increase morbidity and mortality.[41] Dermatitis herpetiformis, a chronic and intensely pruritic blistering rash, is another complication directly linked to celiac disease. Although its cutaneous manifestations may appear isolated, it is pathognomonic for gluten sensitivity and typically resolves with a GFD. Neurologic complications are also documented, including peripheral neuropathy, cerebellar ataxia, seizures, and cognitive impairment, often attributed to chronic immune activation and nutrient malabsorption. Psychiatric conditions such as depression and anxiety are more prevalent in individuals with celiac disease, likely reflecting the interplay between chronic inflammation, restrictive dietary requirements, and the psychosocial burden of a lifelong condition. Reproductive issues represent another area of concern. Women may experience infertility, recurrent miscarriages, low birth weight infants, and adverse pregnancy outcomes if the disease is unrecognized or untreated.[6][41][32] Additionally, individuals with celiac disease are at increased risk for certain infections, including pneumococcal sepsis and pneumonia, even when they adhere to a strict GFD. The ACG guidelines therefore recommend considering pneumococcal vaccination for all individuals diagnosed with celiac disease, particularly those who may not have completed the standard childhood immunization series.[11] Through vigilant clinical management and patient education, many of these complications can be avoided, leading to improved health outcomes and quality of life.

Patient Education

Patient education plays a pivotal role in the long-term management of celiac disease, as the success of treatment relies almost entirely on strict and lifelong adherence to a GFD. Education should begin at the time of diagnosis and continue throughout the patient's lifespan to reinforce knowledge, identify barriers, and support behavioral change. Clinicians must teach patients and caregivers how to identify foods and products that contain gluten, emphasizing careful label reading and recognition of hidden sources. Processed foods, medications, herbal supplements, and even cosmetics may contain gluten, and patients must be trained to avoid these exposures. Preventing cross-contamination in the home is equally essential; for example, using separate cooking utensils, toasters, and cutting boards helps minimize inadvertent exposure. Instructing patients to rely on reputable GFD lists and certified gluten-free products enhances dietary safety and reduces uncertainty. These lists, often curated by national celiac associations and regulatory agencies, provide updated information on safe foods and are especially useful when grocery shopping or eating outside the home. Dining out presents particular challenges due to concerns about cross-contact and miscommunication. Patients benefit from learning strategies such as asking detailed questions about preparation methods, avoiding shared fryers or griddles, and selecting restaurants with gluten-free protocols. Collaboration with a registered dietitian is critical, as dietitians provide individualized nutrition counseling, help create balanced GFD meal plans, and address cultural, social, or financial obstacles to dietary adherence. The psychosocial burden of a lifelong restrictive diet should not be underestimated. Feelings of isolation, anxiety, and frustration are common, especially among adolescents or newly diagnosed adults adapting to major lifestyle changes. Clinicians should normalize these emotions and offer resources such as support groups, online communities, or mental health services. Regular follow-up appointments serve as key opportunities to reassess dietary adherence, monitor symptoms, and reinforce education. Strong patient–provider communication fosters trust and empowers individuals to manage celiac disease effectively, ultimately preventing complications and improving long-term well-being.

Other Issues

The ACG 2023 guidelines provide essential direction for clinicians involved in the diagnosis and management of celiac disease. One critical clinical pearl is that initial screening should rely on tTG-IgA testing, the most sensitive and specific serologic marker for untreated celiac disease. Because IgA deficiency occurs more commonly in individuals with celiac disease than in the general population, clinicians must measure total IgA levels concurrently. In patients with IgA deficiency, IgG-based serologic assays—such as deamidated gliadin peptide IgG—should be used instead. Another important guideline emphasizes that small intestinal biopsy remains the gold standard for diagnosis in most children and adults, requiring multiple samples from distinct duodenal sites to reduce the risk of sampling error. The exception applies to selected pediatric patients with very high tTG-IgA levels and positive EMA, for whom a no-biopsy diagnostic pathway may be appropriate. A central goal of GFD therapy is mucosal healing, and clinicians should set individualized expectations based on patient age and severity of intestinal damage. Tools such as gluten-detection devices in food or stool are discouraged due to poor standardization and uncertain clinical reliability. Similarly, probiotics have insufficient evidence to support routine recommendation. The inclusion of gluten-free oats is endorsed, as studies demonstrate their safety and nutritional benefit when uncontaminated. Another key clinical consideration is the increased risk of

pneumococcal infections in individuals with celiac disease, prompting the recommendation for pneumococcal vaccination regardless of age at diagnosis.[11] Case finding—targeted testing of individuals with symptoms or comorbidities associated with celiac disease—improves detection of previously unrecognized cases. This approach is more efficient and clinically useful than community-wide mass screening, which is not recommended. Clinicians must remain vigilant for associated conditions such as dermatitis herpetiformis, autoimmune thyroid disease, and type-1 diabetes, ensuring comprehensive and timely evaluation. These pearls support accurate diagnosis, reduce missed cases, and inform long-term management practices that optimize patient outcomes.

Enhancing Healthcare Team Outcomes

Optimal outcomes in celiac disease care depend on a coordinated interprofessional approach in which each member of the healthcare team contributes specialized expertise. Primary care physicians and gastroenterologists lead the diagnostic process by recognizing clinical indicators, ordering and interpreting serologic tests, and performing confirmatory biopsies. Nurses play a pivotal role in patient education, symptom assessment, and the coordination of follow-up care. They reinforce dietary instructions and ensure patient understanding during transitions, such as from pediatric to adult care. School nurses are essential advocates for children with celiac disease, ensuring safe meal planning, preventing food sharing, and educating school staff about the seriousness of gluten exposure. Registered dietitians are indispensable members of the interprofessional team, as they provide individualized counseling, optimize dietary adequacy, and address challenges such as label interpretation, cost barriers, and maintaining cultural food practices within the confines of a strict GFD. Psychologists or counselors support patients coping with the chronic nature of celiac disease, helping them manage stress, anxiety, and disruptions to social interactions. Mental health support is critical, as individuals may struggle with feelings of isolation, dietary vigilance fatigue, or frustration related to the financial and logistical burdens of a restrictive diet. Social workers assist families in obtaining resources, such as financial assistance for gluten-free foods, community programs, and educational accommodations. Laboratory professionals contribute by ensuring accuracy in serologic testing and biopsy processing, which are key components of diagnosis and follow-up. The integration of these diverse roles ensures patients receive comprehensive, continuous care. Interprofessional collaboration enhances diagnostic accuracy, strengthens patient education, and improves adherence to treatment. Regular communication among healthcare professionals—such as shared electronic records or multidisciplinary meetings—ensures continuity of care and early recognition of complications. This collaborative model leads to improved clinical outcomes, higher quality of life, and reduced long-term healthcare burdens for individuals with celiac disease.

Conclusion:

In conclusion, celiac disease is a complex, systemic autoimmune disorder that demands a comprehensive and lifelong management strategy. The unequivocal cornerstone of treatment remains a strict, lifelong gluten-free diet, which is essential for achieving symptomatic relief, facilitating mucosal healing, and preventing serious long-term complications such as osteoporosis, infertility, and enteropathy-associated T-cell lymphoma. However, successful management extends far beyond dietary exclusion alone. The journey for a patient with celiac disease involves navigating significant nutritional, social, and psychological challenges, underscoring the necessity of a robust, interprofessional support system. Optimal patient outcomes are achieved through a collaborative model that integrates the expertise of gastroenterologists, primary care physicians, registered dietitians, nurses, and mental health professionals. This team is crucial for ensuring an accurate and timely diagnosis, providing continuous and tailored nutritional education, monitoring for nutrient deficiencies and associated autoimmune conditions, and offering psychosocial support to mitigate the burdens of a restrictive diet. Therefore, an interdisciplinary, patient-centered approach is fundamental to empowering individuals with celiac disease, enhancing their adherence to treatment, and ultimately safeguarding their long-term health and quality of life.

References:

1. Tye-Din JA, Galipeau HJ, Agardh D. Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies. Front Pediatr. 2018;6:350.
2. Austin K, Deiss-Yehiely N, Alexander JT. Diagnosis and Management of Celiac Disease. JAMA. 2024 Jul 16;332(3):249-250.
3. Yu XB, Uhde M, Green PH, Alaedini A. Autoantibodies in the Extraintestinal Manifestations of Celiac Disease. Nutrients. 2018 Aug 20;10(8)
4. Clark R, Johnson R. Malabsorption Syndromes. Nurs Clin North Am. 2018 Sep;53(3):361-374.
5. Sharma P, Baloda V, Gahlot GP, Singh A, Mehta R, Vishnubathla S, Kapoor K, Ahuja V, Gupta SD, Makharia GK, Das P. Clinical, endoscopic, and histological differentiation between celiac disease and tropical sprue: A systematic review. J Gastroenterol Hepatol. 2019 Jan;34(1):74-83.
6. Levescot A, Malamut G, Cerf-Bensussan N. Immunopathogenesis and environmental triggers in coeliac disease. Gut. 2022 Jul 25;71(11):2337-49.
7. Voisine J, Abadie V. Interplay Between Gluten, HLA, Innate and Adaptive Immunity Orchestrates

the Development of Coeliac Disease. Front Immunol. 2021;12:674313.
8. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makharia GK. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2.
9. Jansson-Knodell CL, Hujoel IA, West CP, Taneja V, Prokop LJ, Rubio-Tapia A, Murray JA. Sex Difference in Celiac Disease in Undiagnosed Populations: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019 Sep;17(10):1954-1968.e13.
10. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf JI, Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-2044.
11. Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Am J Gastroenterol. 2023 Jan 01;118(1):59-76.
12. Greco L, Romino R, Coto I, Di Cosmo N, Percopo S, Maglio M, Paparo F, Gasperi V, Limongelli MG, Cotichini R, D'Agate C, Tinto N, Sacchetti L, Tosi R, Stazi MA. The first large population based twin study of coeliac disease. Gut. 2002 May;50(5):624-8
13. Vivas S, Ruiz de Morales JM, Fernandez M, Hernando M, Herrero B, Casqueiro J, Gutierrez S. Age-related clinical, serological, and histopathological features of celiac disease. Am J Gastroenterol. 2008 Sep;103(9):2360-5; quiz 2366.
14. Kori M, Goldstein S, Hofi L, Topf-Olivestone C. Adherence to gluten-free diet and follow-up of pediatric celiac disease patients, during childhood and after transition to adult care. Eur J Pediatr. 2021 Jun;180(6):1817-1823.
15. Cukrowska B, Sowińska A, Bierła JB, Czarnowska E, Rybak A, Grzybowska-Chlebowczyk U. Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota - Key players in the pathogenesis of celiac disease. World J Gastroenterol. 2017 Nov 14;23(42):7505-7518.
16. Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, Rallabhandi P, Shea-Donohue T, Tamiz A, Alkan S, Netzel-Arnett S, Antalis T, Vogel SN, Fasano A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008 Jul;135(1):194-204.e3.
17. Kahrs CR, Chuda K, Tapia G, Stene LC, Mårild K, Rasmussen T, Rønningen KS, Lundin KEA, Kramna L, Cinek O, Størdal K. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ. 2019 Feb 13;364:l231.
18. Mandile R, Maglio M, Mosca C, Marano A, Discepolo V, Troncone R, Auricchio R. Mucosal Healing in Celiac Disease: Villous Architecture and Immunohistochemical Features in Children on a Long-Term Gluten Free Diet. Nutrients. 2022 Sep 07;14(18)
19. Di Sabatino A, Vanoli A, Giuffrida P, Luinetti O, Solcia E, Corazza GR. The function of tissue transglutaminase in celiac disease. Autoimmun Rev. 2012 Aug;11(10):746-53.
20. Elli L, Leffler D, Cellier C, Lebwohl B, Ciacci C, Schumann M, Lundin KEA, Chetcuti Zammit S, Sidhu R, Roncoroni L, Bai JC, Lee AR, Dennis M, Robert ME, Rostami K, Khater S, Comino I, Cebolla A, Branchi F, Verdu EF, Stefanolo JP, Wolf R, Bergman-Golden S, Trott N, Scudeller L, Zingone F, Scaramella L, Sanders DS. Guidelines for best practices in monitoring established coeliac disease in adult patients. Nat Rev Gastroenterol Hepatol. 2024 Mar;21(3):198-215.
21. Butwicka A, Lichtenstein P, Frisén L, Almqvist C, Larsson H, Ludvigsson JF. Celiac Disease Is Associated with Childhood Psychiatric Disorders: A Population-Based Study. J Pediatr. 2017 May;184:87-93.e1.
22. Williams PM, Harris LM, Odom MR. Celiac Disease: Common Questions and Answers. Am Fam Physician. 2022 Jul;106(1):36-43.
23. Guandalini S, Assiri A. Celiac disease: a review. JAMA Pediatr. 2014 Mar;168(3):272-8.
24. Jericho H, Sansotta N, Guandalini S. Extraintestinal Manifestations of Celiac Disease: Effectiveness of the Gluten-Free Diet. J Pediatr Gastroenterol Nutr. 2017 Jul;65(1):75-79.
25. Reunala T, Salmi TT, Hervonen K, Kaukinen K, Collin P. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018 May 12;10(5)
26. Glissen Brown JR, Singh P. Coeliac disease. Paediatr Int Child Health. 2019 Feb;39(1):23-31.
27. Kelly D, Mearin ML, Ribes Koninckx C. Pediatric Celiac Disease: Earlier Diagnosis for Better Lifelong Health. J Pediatr Gastroenterol Nutr. 2018 Nov;67(5):e106.
28. See J, Murray JA. Gluten-free diet: the medical and nutrition management of celiac disease. Nutr Clin Pract. 2006 Feb;21(1):1-15.
29. Bai JC, Ciacci C. World Gastroenterology Organisation Global Guidelines: Celiac Disease February 2017. J Clin Gastroenterol. 2017 Oct;51(9):755-768.
30. Walker MM, Ludvigsson JF, Sanders DS. Coeliac disease: review of diagnosis and

management. Med J Aust. 2017 Aug 21;207(4):173-178.
31. McDermid JM, Almond MA, Roberts KM, Germer EM, Geller MG, Taylor TA, Sinley RC, Handu D. Celiac Disease: An Academy of Nutrition and Dietetics Evidence-Based Nutrition Practice Guideline. J Acad Nutr Diet. 2023 Dec;123(12):1793-1807.e4.
32. Lee AR, Wolf RL, Lebwohl B, Ciaccio EJ, Green PHR. Persistent Economic Burden of the Gluten Free Diet. Nutrients. 2019 Feb 14;11(2)
33. Shah S, Akbari M, Vanga R, Kelly CP, Hansen J, Theethira T, Tariq S, Dennis M, Leffler DA. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014 Sep;109(9):1304-11.
34. Husby S, Murray JA, Katzka DA. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. Gastroenterology. 2019 Mar;156(4):885-889.
35. Pallav K, Leffler DA, Tariq S, Kabbani T, Hansen J, Peer A, Bhansali A, Najarian R, Kelly CP. Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice. Aliment Pharmacol Ther. 2012 Feb;35(3):380-90.
36. Oberhuber G, Mesteri I, Kopf W, Müller H. Demonstration of Trophozoites of G. Lamblia in Ileal Mucosal Biopsy Specimens May Reveal Giardiasis in Patients With Significantly Inflamed Parasite-free Duodenal Mucosa. Am J Surg Pathol. 2016 Sep;40(9):1280-5.
37. Hamdeh S, Micic D, Hanauer S. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1370-1388.
38. Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, Sarles J, Hugot JP, Ginies JL, Dabadie A, Mouterde O, Allez M, Nion-Larmurier I., Groupe D'Etude et de Recherche Sur la Maladie Coeliaque. Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol. 2008 Jul;6(7):753-8.
39. Green PHR, Paski S, Ko CW, Rubio-Tapia A. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. Gastroenterology. 2022 Nov;163(5):1461-1469.
40. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, Fasano A. Celiac disease: a comprehensive current review. BMC Med. 2019 Jul 23;17(1):142